The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Use of a dynamic disease progression model to estimate prevalence and prognosis for patients with urothelial carcinoma (UC) in the United States (US).
 
Sarah Fleming
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Kirk Solo
Employment - Lexidyne
Research Funding - Janssen (Inst)
 
Xuehua Ke
Employment - HealthCore; Janssen Scientific Affairs
Stock and Other Ownership Interests - Anthem, Inc.; Johnson & Johnson
 
Waleed Shalaby
Employment - Janssen Scientific Affairs
Stock and Other Ownership Interests - Johnson & Johnson
 
Arlene O. Siefker-Radtke
Consulting or Advisory Role - AstraZeneca; Bavarian Nordic; BioClin Therapeutics; Bristol-Myers Squibb; EMD Serono; Genentech; Inovio Pharmaceuticals; Janssen; Merck; NCCN; Nektar; Seagen
Research Funding - BioClin Therapeutics; Bristol-Myers Squibb; Janssen; Merck Sharp & Dohme; Michael and Sherry Sutton Fund for Urothelial Cancer; Nektar; NIH; Takeda
Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.